Super Group: Canaccord Genuity maintains Buy, PT raised to $17 from $15.

Super Group: Canaccord Genuity maintains Buy, PT raised to $17 from $15.

Canaccord Genuity Group has maintained its "buy" rating on Madrigal Pharmaceuticals (NASDAQ: MDGL) and raised its price target to $17.00 from $15.00, according to a report released on Wednesday [1]. The firm's new price objective suggests a potential upside of 27.38% from the company's current price. This move comes amidst a wave of positive analyst ratings and increased price targets for Madrigal Pharmaceuticals.

Madrigal Pharmaceuticals reported a significant rise in revenue of 1357.5% year-over-year, with quarterly earnings beating expectations at ($1.90) EPS against a consensus of ($3.48) [1]. The company's lead product candidate, resmetirom, a liver-directed thyroid hormone receptor beta agonist, is in Phase 3 clinical trials for treating non-alcoholic steatohepatitis (NASH).

Several other research firms have also weighed in on MDGL. UBS Group lifted their price target on Madrigal Pharmaceuticals from $441.00 to $458.00 and gave the stock a "buy" rating in a report on Friday, May 2nd [1]. JMP Securities restated a "market outperform" rating and set a $443.00 price objective on shares of Madrigal Pharmaceuticals in a research report on Thursday, April 24th [1]. B. Riley reiterated a "buy" rating and issued a $460.00 price target (up previously from $422.00) on shares of Madrigal Pharmaceuticals in a research report on Friday, May 2nd [1]. Finally, Wall Street Zen upgraded Madrigal Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Monday, May 5th [1].

Based on data from MarketBeat, Madrigal Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $421.63 [1]. The stock's 50-day simple moving average is $297.49 and its 200-day simple moving average is $312.32 [1]. The company has a market cap of $7.46 billion, a P/E ratio of -18.60, and a beta of -1.02 [1].

Madrigal Pharmaceuticals last released its quarterly earnings data on Tuesday, August 5th [1]. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.48) by $1.58 [1]. The company's revenue was up 1357.5% on a year-over-year basis, reaching $212.80 million during the quarter [1]. As a group, equities research analysts predict that Madrigal Pharmaceuticals will post -23.47 EPS for the current year [1].

References:
[1] https://www.marketbeat.com/instant-alerts/canaccord-genuity-group-forecasts-strong-price-appreciation-for-madrigal-pharmaceuticals-nasdaqmdgl-stock-2025-08-06/